Aadi Bioscience Inc
AADI.O- Latest Trade
- trading higher7.12USD
- 0
- 0.00%
- As of Mar 30 2023. Values delayed up to 15 minutes
- Today's Range
- -- - --
- 52 Week Range
- 6.80 - 18.47
- Previous Close
- 7.12
- Open
- 0.00
- Volume
- 302.00
- 3 Month Average Trading Volume
- 2.64
- Shares Out (Mil)
- 24.40
- Market Cap
- 167.11
- Forward P/E
- -2.70
- Dividend Yield
- 0.00
Key Statistics
1.60 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 15.21
- Price To Book (Quarterly)
- 0.99
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -37.54
- Return On Equity (TTM)
- -34.50
2021 (millions USD)
About Aadi Bioscience Inc (AADI.O)
Company Information
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company, The Company is engaged in developing precision therapies for genetically-defined cancers. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
Address
17383 Sunset Avenue, Suite A250PACIFIC PALISADES, CA
90272
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Neil Desai
- Executive Chairman of the Board
- Scott Giacobello
- Interim Chief Executive Officer, President, Chief Financial Officer, Treasurer
- Loretta M. Itri
- Chief Medical Officer
- Behzad Aghazadeh
- Independent Director
- Caley Castelein
- Independent Director
- Anupam Dalal
- Independent Director
- Karin Hehenberger
- Independent Director
- Mohammad Hirmand
- Independent Director
- Richard Maroun
- Independent Director
- Emma Reeve
- Independent Director
Latest News
- MarketsU.S. RESEARCH ROUNDUP Api Group, Apria, Zynga
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Api Group, Apria and Zynga, on Tuesday.
- MarketsApple, Zoom, Abercrombie, Walt Disney
Wall Street's main indexes slipped on Tuesday, with the Nasdaq lagging the most as rising Treasury yields weighed on major technology stocks, while gains in banking and energy stocks helped limit broader market losses.
- MarketsZoom, Walt Disney, Best Buy
U.S. stock indexes were set for a sluggish start on Tuesday as rising Treasury yields weighed on major technology stocks, while bank shares extended gains as investors priced in early monetary policy tightening by the Federal Reserve.
- MarketsZoom, Udemy, Walt Disney
U.S. stock index futures fell on Tuesday as rising Treasury yields weighed on major technology stocks, while bank shares extended gains as investors priced in an early policy tightening by the Federal Reserve.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,968.50 | 0.08% |
| Copper | 788.00 | 0.79% |
| Brent Crude Oil | 78.53 | 0.32% |
| CBOT Soybeans | 1,481.25 | 0.27% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,027.81 | -- |
| Euro STOXX 50 | 4,283.81 | 1.24% |
| FTSE 100 | 7,620.89 | 0.75% |
| Nikkei 225 | 27,782.93 | 0.36% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes